Illuminating Breast Cancer Recurrence Risk  |   > Search     |   Take me to: Oncotype - Home Healthcare Professionals - Home Oncotype DX Logistics - Home About Oncotype DX About Recurrence Oncotype DX Development Health Insurance Coverage Frequently Asked Questions Glossary Helpful Links About Oncotype DX What is Oncotype DX? Who is Oncotype DX For? How is Oncotype DX Performed? How Can Oncotype DX Benefit Me? Oncotype DX Results How Do I Get a Test? About Recurrence Oncotype DX Development Health Insurance Coverage Frequently Asked Questions Glossary Helpful Links About Oncotype DX Oncotype DX® is the first cancer test that uses the unique gene expression profile of a patient's tumor to quantify the likelihood that her breast cancer will recur. Oncotype DX can provide doctors with a better understanding of the aggressiveness of individual tumors, and can also assess a patient's likely benefit from chemotherapy.1 This information may provide an added measure of confidence that the treatment plan is tailored to the patient's individual disease. The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) asked panels to develop consensus recommendations for specific areas of cancer care to help doctors give patients clinically appropriate treatment. Oncotype DX is included in both the ASCO 2007 Update of Recommendations for the User of Tumor Markers in Breast Cancer and the NCCN Clinical Practice Guidelines in Oncology Breast Cancer , specifically for use in certain subgroups of patients with early stage, node-negative, estrogen receptor-positive breast cancer. For more information, see ASCO Patient Guide: Tumor Markers for Breast Cancer. A recent study has also shown that Oncotype DX may be informative for newly diagnosed women who are post-menopausal and have node-positive, hormonal receptor-positive breast cancer. Click here to learn more about the Oncotype DX Breast Cancer Assay. Genomic Health's® vision is to prolong and enhance the lives of patients with cancer by leading the application of genomics to clinical practice. Oncotype DX Patient Education Brochures: English & Spanish (click on image to view): English Spanish 1 The data on chemotherapy benefit is derived from the NSABP Study B-20 which compared hormonal therapy alone versus CMF based chemotherapy and hormonal therapy. What's New? August 5, 2008 Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress July 29, 2008 Genomic Health to Announce Second Quarter 2008 Financial Results and Host Conference Call on Tuesday, August 5, 2008

© 2008 Genomic Health, Inc.  All rights reserved. | Home | Contact Us | Privacy | Terms and Conditions |